title: No accumulation of a prophylactic dose of nadroparin in moderate renal insufficiency.
abstract: BACKGROUND
  Low-molecular-weight heparins (LMWHs) have been shown to accumulate in patients with renal insufficiency, especially in therapeutic dosages. Although no appropriate studies have been conducted for prophylactic dosages of nadroparin, dose reduction is sometimes recommended, especially for high prophylactic dosages. We assessed accumulation of a prophylactic dose of 5700 IU subcutaneous nadroparin once daily in patients with renal insufficiency.
  
  
  METHODS
  We conducted a prospective cohort study and measured peak anti-Xa activity four hours after subcutaneous nadroparin injection on day 1, 3, 5 and if possible day 10 in adults with and without renal insufficiency defined as a glomerular filtration rate (GFR) below or above 50 ml/min/1.73 m2. Patients with a GFR below 10 ml/min/1.73 m2 were excluded.
  
  
  RESULTS
  We included 14 patients in each group. In the group with renal failure 12 patients had a GFR between 30 and 50 ml/min/1.73 m2. Peak anti-Xa activity showed a high interindividual variability, but was fairly constant within each patient. There was no rise in peak anti-Xa activity on day 3 and 5 after consecutive administration. In the group with normal renal function, peak anti-Xa activity declined on day 5 compared with day 1 (p = 0.005).
  
  
  CONCLUSIONS
  Prophylactic dosages of nadroparin showed no accumulation in patients with a GFR between 30-50 ml/min/1.73 m2. Dose reduction in this group could lead to suboptimal thromboprophylaxis. Due to underrepresentation of patients with a GFR < 30 ml/min/1.73 m2 (n = 2), we cannot give recommendations for this group.
authors.affiliation: Department of Hospital Pharmacy, Erasmus Medical Centre, Rotterdam, the Netherlands.
authors.forename: F
authors.initials: F
authors.lastname: Atiq
authors.forename: P M L A
authors.initials: PM
authors.lastname: van den Bemt
authors.forename: F W G
authors.initials: FW
authors.lastname: Leebeek
authors.forename: T
authors.initials: T
authors.lastname: van Gelder
authors.forename: J
authors.initials: J
authors.lastname: Versmissen
mesh_terms: D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage / Q000493:pharmacokinetics*; D065427:Factor Xa Inhibitors; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D017762:Nadroparin / Q000008:administration & dosage / Q000493:pharmacokinetics*; D011446:Prospective Studies; D051437:Renal Insufficiency / Q000378:metabolism*; D054556:Venous Thromboembolism / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D017762:Nadroparin